40 related articles for article (PubMed ID: 22074578)
21. [The antipsychotic drug aripiprazole (ABILIFY)].
Hirose T; Mamiya N; Yamada S; Taguchi M; Kameya T; Kikuchi T
Nihon Yakurigaku Zasshi; 2006 Nov; 128(5):331-45. PubMed ID: 17102579
[No Abstract] [Full Text] [Related]
22. Aripiprazole. Abilitat, OPC 14597.
Drugs R D; 2002; 3(1):25-7. PubMed ID: 11881525
[No Abstract] [Full Text] [Related]
23. Dopamine partial agonists: a new class of antipsychotic.
Lieberman JA
CNS Drugs; 2004; 18(4):251-67. PubMed ID: 15015905
[TBL] [Abstract][Full Text] [Related]
24. Aripiprazole: profile on efficacy and safety.
Goodnick PJ; Jerry JM
Expert Opin Pharmacother; 2002 Dec; 3(12):1773-81. PubMed ID: 12472374
[TBL] [Abstract][Full Text] [Related]
25. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
Costentin J
Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
[TBL] [Abstract][Full Text] [Related]
26. Partial agonism and schizophrenia.
Bolonna AA; Kerwin RW
Br J Psychiatry; 2005 Jan; 186():7-10. PubMed ID: 15630117
[No Abstract] [Full Text] [Related]
27. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify).
Bergman J
Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Grunder G; Carlsson A; Wong DF
Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
[TBL] [Abstract][Full Text] [Related]
29. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist.
Hirose T; Kikuchi T
J Med Invest; 2005 Nov; 52 Suppl():284-90. PubMed ID: 16366516
[TBL] [Abstract][Full Text] [Related]
30. Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
Wood M; Reavill C
Expert Opin Investig Drugs; 2007 Jun; 16(6):771-5. PubMed ID: 17501690
[TBL] [Abstract][Full Text] [Related]
31. [In vitro pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y; Kobayashi H
Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):265-71. PubMed ID: 25492361
[No Abstract] [Full Text] [Related]
32. Aripiprazole in the treatment of Alzheimer's disease.
De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
[TBL] [Abstract][Full Text] [Related]
33. Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence.
Vergne DE; Anton RF
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):50-4. PubMed ID: 20201815
[TBL] [Abstract][Full Text] [Related]
34. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.
DeLeon A; Patel NC; Crismon ML
Clin Ther; 2004 May; 26(5):649-66. PubMed ID: 15220010
[TBL] [Abstract][Full Text] [Related]
35. Aripiprazole.
McGavin JK; Goa KL
CNS Drugs; 2002; 16(11):779-86; discussion 787-8. PubMed ID: 12383035
[TBL] [Abstract][Full Text] [Related]
36. Pituitary microadenoma treated with antipsychotic drug aripiprazole.
Wix-Ramos RJ; Paez R; Capote E; Ezequiel U
Recent Pat Endocr Metab Immune Drug Discov; 2011 Jan; 5(1):58-60. PubMed ID: 22074578
[TBL] [Abstract][Full Text] [Related]
37. Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.
De Berardis D; Fornaro M; Serroni N; Marini S; Piersanti M; Cavuto M; Valchera A; Mazza M; Girinelli G; Iasevoli F; Perna G; Martinotti G; Di Giannantonio M
Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):30-7. PubMed ID: 24372345
[TBL] [Abstract][Full Text] [Related]
38. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia.
Hoffer ZS; Roth RL; Mathews M
Psychosomatics; 2009; 50(4):317-24. PubMed ID: 19687170
[TBL] [Abstract][Full Text] [Related]
39. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
40. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
Keck PE; McElroy SL
Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
